Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disorders

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 174-184

  Kumar, Kushal ^a   Sharma, Sorabh ^a   Kumar, Puneet ^a   Deshmukh, Rahul ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Addiction; Anxiety; CNS disorders; Depression; GABA; Neurodegenerative disorders

Indexed keywords

2 HYDROXYSACLOFEN; 2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 3 AMINOPROPANEPHOSPHINIC ACID; 3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 3 AMINOPROPYL(DIFLUOROMETHYL)PHOSPHINIC ACID; 3 AMINOPROPYL(METHYL)PHOSPHINIC ACID; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 3 [1 [3 [(CYCLOHEXYLMETHYL)HYDROXYPHOSPHINYL] 2 HYDROXYPROPYLAMINO]ETHYL]BENZOIC ACID; 4 AMINO 3 PHENYLBUTYRIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR LIGAND; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ARBACLOFEN PLACARBIL; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; CGP 44532; LESOGABERAN; METABOTROPIC RECEPTOR; MUSCIMOL; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; PHACLOFEN; PROTON PUMP INHIBITOR; SACLOFEN; SCOPOLAMINE; TETRODOTOXIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; AUTISM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DRUG DEPENDENCE; DYSTONIA; EPILEPSY; GASTROESOPHAGEAL REFLUX; HUMAN; HUNTINGTON CHOREA; HYPOTHERMIA; MEMORY DISORDER; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MUSCLE RELAXATION; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SEDATION; SIDE EFFECT; SPASTICITY; STIFF MAN SYNDROME;

ADDICTION; ANXIETY; CNS DISORDERS; DEPRESSION; GABA; NEURODEGENERATIVE DISORDERS;

ANXIETY; CENTRAL NERVOUS SYSTEM DISEASES; DEPRESSION; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, GABA-B; SUBSTANCE-RELATED DISORDERS;

EID: 84881011643     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.07.003     Document Type: Review

References (129)

1. Allen KL, Waldvogel HJ, Glass M, Faull RL. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009;37(4): 266-81.
2. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl. 1): 1-27.
3. Anju TR, Jayanarayanan S, Paulose CS. Decreased GABAB receptor function in the cerebellum and brain stem of hypoxic neonatal rats: role of glucose, oxygen and epinephrine resuscitation. J Biomed Sci 2011;18(1):31.
4. Balanaa B, Maslennikovb I, KwiatkowskibW, Sterna KM, Bahimaa L, Choeb S, et al. Mechanism underlying selective regulation of G protein-gated inwardly rectifying potassium channels by the psychostimulant-sensitive sorting nexin 27. PNAS 2011;108(14): 5831-6.
5. Benke D, Zemoura K, Maier PJ. Modulation of cell surface GABAB receptors by desensitization, trafficking and regulated degradation.World J Biol Chem 2012;3(4): 61-72.
6. Berta S, Ki-Shuk S, Gunyong A, Harald H, Gert L. Hippocampal levels of phosphorylated protein kinase a (phosphor-S96) are linked to spatial memory enhancement by SGS742. Hippocampus 2009;19: 90-8.
7. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABAB receptors. Neuron 2010;66(1): 101-13.
8. Bianchi M, Panerai AE. Reversal of scopolamine-induced amnesia by the GABAB receptor antagonist CGP 35348 in the mouse. Brain Res Cogn Brain Res 1993;1(2): 135-6. (Pubitemid 23131133)
9. Billinton A, Baird VH, Thom M, Duncan JS, Upton N, Bowery NG. GABAB receptor autoradiography in hippocampal sclerosis associated with human temporal lobe epilepsy. Br J Pharmacol 2001;132(2): 475-80. (Pubitemid 32142361)
10. Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec (Hoboken) 2011;294(10): 1646-52.
11. Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 1987;20: 365-83. (Pubitemid 17048701)
12. Burman KJ, Ige AO,White JH, Marshall FH, Pangalos MN, Emson PC, et al. GABAB receptor subunits, R1 and R2, in brainstem catecholamine and serotonin neurons. Brain Res 2003;970: 35-46. (Pubitemid 36423180)
13. Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, et al. 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Exp Neurol 2000;163: 191-9. (Pubitemid 30314374)
14. Castelli MP, Casu A, Casti P, Lobina C, Carai Mauro AM, Colombo G, et al. Characterization of COR627 and COR628, two novel positive allostericmodulators of the GABAB receptor. J Pharmacol Exp Ther 2012;310: 529-38.
15. Catena-Dell'Osso M, Marazziti D. Non-monoaminergic approaches in search of novel antidepressants. Clin Neuropsychiatry 2012;9(4): 182-3.
16. Chalifoux JR, Carter AG. GABAB receptormodulation of voltage-sensitive calciumchannels in spines and dendrites. J Neurosci 2011;31(11): 4221-32.
17. Chiodi V, UchigashimaM, Beggiato S, Ferrante A, ArmidaM,Martire A, et al. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2012;45(3): 983-91.
18. Cimarosti H, Kantamneni S, Henley JM. Ischaemia differentially regulates GABAB receptor subunits in organotypic hippocampal slice cultures. Neuropharmacology 2009;56(8): 1088-96.
19. Cozzia A, Melia E, Carlaa V, Pellicciarib R, Moronia F, Pellegrini-Giampietroa DE. Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology 2002;43(2): 119-30.
20. Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 2005;26(1): 36-43. (Pubitemid 40052708)
21. Cryan JF, Leonard BE. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 2000;15: 113-35. (Pubitemid 30199285)
22. Cryan JF, Slattery DA. GABAB receptors and depression: current status. In: Blackburn TP, editor. GABAB receptor pharmacology: a tribute to Norman Bowery. Advances in PharmacologyNew York: Academic Press; 2010.
23. Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoehl K, et al. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N, N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 2004;310(3): 952-63. (Pubitemid 39108915)
24. Cytril G, ValerioM,Marc L, FredericN, Robert IVWG, Jean-Philippe P. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 2009;S60: 43-56.
25. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf 2004;27(11): 799-818. (Pubitemid 39243562)
26. David AS, Sandrine D, John FC. GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. JPET 2005;312: 290-6.
27. Dittman JS, Regehr WG. Contributions of calcium-dependent and calcium-independent mechanisms to presynaptic inhibition at a cerebellar synapse. J Neurosci 1996;16: 1623-33. (Pubitemid 26145940)
28. Dunlap K, Fischbach GD. Neurotransmitters decrease the calcium conductance activated by depolarization of embryonic chick sensory neurons. J Physiol (Lond) 1981;317: 519-35. (Pubitemid 12205891)
29. Dutar P, Nicoll RA. A physiological role for GABAB receptors in the central nervous system. Nature 1988;332(6160): 156-8. (Pubitemid 18083559)
30. Eduardo EB. GABAB receptors: structure, functions, and clinical implications. Neurology 2012;78(8): 578-84.
31. Enna SJ, Bowery NG. GABAB receptor alterations as indicators of physiological and pharmacological function. Biochem Pharmacol 2004;68: 1541-8. (Pubitemid 39286458)
32. Fadda P, Scherma M, Fresu A, Collu M, FrattaW. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003;50: 1-6. (Pubitemid 37034107)
33. Fatemi SH, Folsom TD, Reutiman TJ, Thuras PD. Expression of GABAB receptors is altered in brains of subjects with autism. Cerebellum 2009;8(1): 64-9.
34. Fatemi SH, Reutiman TJ, Folsom TD, Rooney RJ, Patel DH, Thuras PD. mRNA and protein levels for GABAAα4, α5, β1 and GABABR1 receptors are altered in brains fromsubjects with autism. J Autism Dev Disord 2010;40(6): 743-50.
35. Ferrari R, NoveÁ re le, PicciottoMR, Changeux JP, ZolilM. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci 2001;15: 1810-8. (Pubitemid 35471906)
36. Filip M, Frankowska M. GABAB receptors in drug addiction. Pharmacol Rep 2008;60: 755-70. [ISSN 1734-1140].
37. Florey E. GABA: history and perspectives. Can J Physiol Pharmacol 1991;69(7): 1049-56.
38. Franek M, Vaculin S, Rokyta R. GABA(B) receptor agonist baclofen has non-specific antinociceptive effect in the model of peripheral neuropathy in the rat. Physiol Res 2004;53(3): 351-5. (Pubitemid 38797292)
39. Fransson B, Silberg DG, Niazi M,Miller F, Ruth M, Holmberg AA. Effect of food on the bioavailability of lesogaberan given as an oral solution or asmodified-release capsules in healthy male volunteers. Int J Clin Pharmacol Ther 2012;50(4): 307-14.
40. Froestl W. Chemistry and pharmacology of GABAB receptor ligands. Adv Pharmacol 2010;58: 19-62.
41. FroestlW, Gallagher M, Jenkins H,Madrid A,Melcher T, Teichman S, et al. SGS742: the first GABAB receptor antagonist in clinical trials. Biochem Pharmacol 2004;68: 1479-87. (Pubitemid 39286451)
42. Fuchs RA, Evans KA, Ledford CC, Parker MP, Case JM, Mehta RH, et al. The role of the dorsomedial prefrontal cortex, basolateral amygdala, and dorsal hippocampus in contextual reinstatement of cocaine seeking in rats.Neuropsychopharmacology 2005;30: 296-309. (Pubitemid 40129481)
43. Galvana A, Hua X, Smitha Y, Wichmanna T. Localization and pharmacological modulation of GABA-B receptors in the globus pallidus of Parkinsonian monkeys. Exp Neurol 2011;229(2): 429-39.
44. Gambardella A,Manna I, Labate A, Chifari R, La Russa A, Serra P, et al. GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 2003;60(4): 560-3. (Pubitemid 36246069)
45. Gassman M, Bettler B. Regulation of neuronal GABAB receptor functions by subunit composition. Neuroscience 2012;13: 380-94.
46. Ghose S,WinterMK, McCarson KE, Tamminga CA, Enna SJ. The GABAB receptor as a target for antidepressant drug action. Br J Pharmacol 2011;162(1): 1-17.
47. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992;15(4): 276-88. [Aug].
48. Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63(4): 584-8.
49. Haense C, Kalbe E, Herholz K, Hohmann C, Neumaier B, Krais R, et al. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging 2012;33(5): 867-77.
50. Hallworth NW, Bevan MD. Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors. J Neurosci 2005;25(27): 6304-15. (Pubitemid 40962525)
51. Hampsona DR, Aduseia DC, Paceya Laura KK. The neurochemical basis for the treatment of autismspectrumdisorders and Fragile X Syndrome. BiochemPharmacol 2011;81(9): 1078-86.
52. Han HA, Cortez MA, Snead OS. GABAB receptor and absence epilepsy. US: National Center for Biotechnology Information; 2012.
53. Hawrot E, Xiao Y, Shi QL, Norman D, Kirkitadze M, Barlow PN. Demonstration of a tandem pair of complement protein modules in GABAB receptor 1a. FEBS Lett 1998;432: 103-8. (Pubitemid 28473255)
54. Helm KA, Haberman RP, Dean SL, Hoyt EC, Melcher T, Lund PK, et al. GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacology 2005;48(7): 956-64. (Pubitemid 40602603)
55. Hillman R, Sinani J, Pendleton R. The role of the GABA(B) receptor and calcium channels in a Drosophila model of Parkinson's disease. Neurosci Lett 2012;516(2): 167-70.
56. Ho BL, Shih PY. Results of intrathecal baclofen therapy on spasticity in patients with brain injury. Ideggyogy Sz 2012;65(7-8): 243-8.
57. Holtzman DM,Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011;3:77sr1.
58. Hotsenpiller G, Wolf ME. Baclofen attenuates conditioned locomotion to cues associated with cocaine administration and stabilizes extracellular glutamate levels in rat nucleus accumbens. Neuroscience 2003;118: 123-34. (Pubitemid 36369537)
59. Hyland NP, Cryan JF. A gut feeling about GABA: focus on GABAB receptors. Front Pharmacol 2010;1:124.
60. Inaba Y, D'AntuonoM, Bertazzoni G, Biagini G, Avoli M. Diminished presynaptic GABA(B) receptor function in the neocortex of a genetic model of absence epilepsy. Neurosignals 2009;17(2): 121-31.
61. Jacobson LH, Cryan JF. Evaluation of the anxiolytic-like profile of theGABAB receptor positive modulator CGP7930 in rodents. Neuropharmacology 2008;54: 854-62.
62. Jacobson LH, Bettler B, Kaupmann K, Cryan JF. Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. Psychopharmacology (Berl) 2007;190: 541-53. (Pubitemid 46204471)
63. Jayaram P, Steketee JD. Effects of cocaine-induced behavioural sensitization on GABA transmission within rat medial prefrontal cortex. Eur J Neurosci 2005;21(7): 2035-9. (Pubitemid 40685883)
64. Jensen AA, Spalding TA. Allostericmodulation of G-protein coupled receptors. Eur J Pharm Sci 2004;21: 407-20.
65. Jerlhag E, Emgel JA. Ghrelin receptor antagonist attenuates nicotine-induced locomotor stimulation, accumbal domain release and conditioned place preference in mice. Drug Alcohol Depend 2011;117: 126-31.
66. Johnston T, Duty S. Changes in GABA(B) receptor mRNA expression in the rodent basal ganglia and thalamus following lesion of the nigrostriatal pathway. Neuroscience 2003;120: 1027-35.
67. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 1991;16: 223-44.
68. Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S, Mickel SJ, et al. Expression cloning of GABA-B receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997;386: 239-46. (Pubitemid 27142503)
69. Kerr DI, Ong J. GABA agonists and antagonists. Med Res Rev 1992;12: 593-636.
70. Kim GH. Arbaclofen placarbil decreases reflux with good tolerability in patients with gastroesophageal reflux disease. J Neurogastroenterol Motil 2010;16(4): 444-5.
71. Kleppner SR, Tobin AJ. GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. Expert Opin Ther Targets 2001;5(2): 219-39.
72. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci 2012;32(27): 9217-27.
73. Kobayashi K, Takei H, Yamamoto K, Hatanaka H, Koshikawa N. Kinetics of GABAB autoreceptor-mediated suppression of GABA release in rat insular cortex. 2012;107(5): 1431-42.
74. KoekW, France CP, Cheng K, Rice KC. GABAB receptor-positive modulators: enhancement of GABAB receptor agonist effects in vivo. J Pharmacol Exp Ther 2010;335: 163-71.
75. Koob GF. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 2006;101: 23-30. (Pubitemid 44199493)
76. Koulen PL,Malitschek B, Kuhn R, Bettler B,Wässle H, Brandstätter JH. Presynaptic and postsynaptic localization of GABAB receptors in neurons of the rat retina. Eur J Neurosci 1998;10: 1446-56. (Pubitemid 28330587)
77. Krishnan GP, Bazhenov M. Ionic dynamics mediate spontaneous termination of seizures and postictal depression state. J Neurosci 2011;31(24): 8870-82.
78. Lapin. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 2001;7(4): 471-81. (Pubitemid 34263878)
79. Lee YH, Yang BC, Lee ES, Chung JI, Koh PO, ParkMS, et al.Modulation by the GABAB receptor siRNA of ethanol mediated PKA-α, CaMKII, and p-CREB intracellular signaling in prenatal rat hippocampal neurons. Anat Cell Biol 2011;44(3): 210-7.
80. Lhuillier L, Mombereau C, Cryan JF, Kaupmann K. GABAB receptor positive modulation decreases selective molecular and behavioral effects of cocaine.Neuropsychopharmacology 2007;32(2): 388-98. (Pubitemid 46106945)
81. Li YS, Hong YF, He J, Lin JX, Shan YL, Fu DY, et al. Effects of magnolol on impairment of learning and memory abilities induced by scopolamine in mice. Biol Pharm Bull 2013;36(5): 764-71.
82. Lyden PD, Jackson-Friedman C, Shin C, Hassid S. Synergistic combinatorial stroke therapy: a quantal bioassay of a GABA agonist and a glutamate antagonist. Exp Neurol 2000;163(2): 477-89. (Pubitemid 30399098)
83. Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen CC, Zenner MT, et al. Characterization of (R, S)-5,7-di-tert-butyl-3-hydroxy-3- trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br J Pharmacol 2008;154(4): 797-811. (Pubitemid 351821586)
84. Mannoury la Cour C, Hanoun N, Melfort M, Hen R, Lesch KP, Hamon M, et al. GABAB receptors in 5-HT transporter- and 5-HT1A receptor-knock-out mice: further evidence of a transduction pathway shared with 5-HT1A receptors. J Neurochem 2004;89: 886-96. (Pubitemid 38684736)
85. Marescaux C, Vergnes M, Bernasconi R. GABAB receptor antagonists: potential new anti-absence drugs. J Neural Transm Suppl 1992;35: 179-88.
86. Marsden IT,Minamide LS, Bamburg JR. Amyloid-beta-induced amyloid-beta secretion: a possible feed-forwardmechanism in Alzheimer's disease. J Alzheimers Dis 2011;24: 681-91.
87. Mizoguchi H, Yamada K. Pharmacologic treatment with GABAB receptor agonist of methamphetamine-induced cognitive impairment in mice. Curr Neuropharmacol 2011;9(1): 109-12.
88. Mizuno H, Fujikake N, Wada K, Nagai Y. α-Synuclein transgenic Drosophila as a model of Parkinson's disease and related synucleinopathies. SAGE-Hindawi access to research Parkinson's disease volume; 2011. http://dx.doi.org/10.4061/2011/212706. [Article ID 212706, 7 pp.].
89. Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten H, Cryan JF. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 2005;16(3): 307-10. (Pubitemid 40364596)
90. Moutoussis M, Orrell W. Baclofen therapy is associated with Lewy body dementia. Br J Psychiatry 1996;169(6):795. (Pubitemid 26419489)
91. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003;37(4): 133-46.
92. Nightingale S. Autism spectrum disorders. Nat Rev Drug Discov 2012;11: 745-6.
93. Nomura S, Kagawa Y, Kida H, Maruta Y, Imoto H, Fujii M, et al. Effects of intrathecal baclofen therapy on motor and cognitive functions in a rat model of cerebral palsy. J Neurosurg Pediatr 2012;9(2): 209-15.
94. Notenboom RGE, Hampson DR, Jansen GH, van Rijen PC, Veelen CWM, Nieuwenhuizen Ov, et al. Up-regulation of hippocampalmetabotropic glutamate receptor 5 in temporal lobe epilepsy patients. Brain 2006;129: 96-107. (Pubitemid 43063762)
95. Nowak G, Partyka A, Palucha A, Szewczyk B, Wierońska JM, Dybała M, et al. Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol 2006;149(5): 581-90. (Pubitemid 44658519)
96. Oblak AL, Gibbs TT, Blatt GJ. Decreased GABAB receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem 2010;114(5): 1414-23.
97. Obrietan K, van den Pol A. GABAB receptor-mediated regulation of glutamate-activated calcium transients in hypothalamic and cortical neuron development. J Neurophysiol 1999;82(1): 94-102. [July 1]. (Pubitemid 29330064)
98. Paluszkiewicz SM, Martin BS, HuntsmanMM. Fragile X Syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci 2011;33: 349-64.
99. Pang KC, Nocera R. Interactions between 192-IgG saporin and intraseptal cholinergic and GABAergic drugs: role of cholinergicmedial septal neurons in spatialworkingmemory. Behav Neurosci 1999;113: 265-75. (Pubitemid 29230935)
100. ParentMB, BaxterMG. Septohippocampal acetylcholine: involved in but not necessary for learning and memory? Learn Mem 2004;11: 9-20. (Pubitemid 38167053)
101. Perry TL, Javoy-Agid F, Agid Y, Fibiger HC. Striatal GABAergic neuronal activity is not reduced in Parkinson's disease. J Neurochem 1983;40(4): 1120-3. (Pubitemid 13163345)
102. Peters HC, Kämmer G, Volz A, Kaupmann K, Ziegler A, Bettler B, et al. Mapping, genomic structure, and polymorphisms of the human GABABR1 receptor gene: evaluation of its involvement in idiopathic generalized epilepsy. Neurogenetics 1998;2(1): 47-54.
103. Peterson NE, Froestl W, Markou A. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology 2004;172(2): 179-86. (Pubitemid 38388767)
104. Pilc A, Nowak G. GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc) 2005;41(11): 755-66. (Pubitemid 43074784)
105. Pinard A, Seddik R, Bettler B. GABAB receptors: physiological functions andmechanisms of diversity. Adv Pharmacol 2010;58: 231-55.
106. Princivalle AP, Duncan JS, Thom M, Bowery NG. Studies of GABAB receptors labeled with [3H]-CGP62349 in hippocampus resected from patients with temporal lobe epilepsy. Br J Pharmacol 2002;136(8): 1099-106. (Pubitemid 34970061)
107. Rowlett JK, Cook JM, Duke AN, Platt DM. Selective antagonism of GABAA receptor subtypes: an in vivo approach to exploring the therapeutic and side effects of benzodiazepinetype drugs. CNS Spectr 2005;10(1): 40-8. (Pubitemid 40139742)
108. Sachais BA, Logue JN, CareyMS. Baclofen, a newantispastic drug. A controlled,multicenter trial in patients with multiple sclerosis. Arch Neurol 1977;34(7): 422-8. (Pubitemid 8141201)
109. Salzmann A, Malafosse A. Genetics of temporal lobe epilepsy: a review. Epilepsy Res Treat 2012: 1-19.
110. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15: 264-70. (Pubitemid 24210734)
111. Sharma AC, Kulkarni SK. (+/-)Baclofen sensitive scopolamine-induced short-term memory deficits in mice. Indian J Exp Biol 1993;31(4): 348-52. (Pubitemid 23142042)
112. Slattery DA, Markou A, Froestl W, Cryan JF. The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the rewardfacilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology 2005;30(11): 2065-72. (Pubitemid 43093505)
113. Steiger JL, Bandyopadhyay S, Farb DH, Russek SJ. cAMP response element-binding protein, activating transcription factor-4, and upstreamstimulatory factor differentially control hippocampal GABABR1a and GABABR1b subunit gene expression through alternative promoters. J Neurosci 2004;24: 6115-26. (Pubitemid 38891102)
114. Storey E, Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993;116(5): 1201-22. (Pubitemid 23329890)
115. Sziráki I, Sershen H, HashimA, Lajtha A. Receptors in the ventral tegmental areamediating nicotine-induced dopamine release in the nucleus accumbens. Neurochem Res 2002;27(3): 253-61. (Pubitemid 34275687)
116. Taniyama K, Niwa M, Kataoka Y, Yamashita K. Activation of protein-kinase-C suppresses the gammaaminobutyric acid B receptor-mediated inhibition of the vesicular release of noradrenaline and acetylcholine. J Neurochem 1992;58: 1239-45.
117. Teichgraber LA, Lehmann TN, Meencke HJ,Weiss T, Nitsch R, Deisz RA. Impaired function of GABAB receptors in tissues from pharmacoresistant epilepsy patients. Epilepsia 2009;50(7): 1697-716.
118. Tuttolomondo A, Di Sciacca R, Di Raimondo D, Arnao V, Renda C, Pinto A, et al. Neuron protection as a therapeutic target in acute ischemic stroke. Curr Top Med Chem 2009;9(14): 1317-34.
119. Ueda Y, Tsuru N. Simultaneous monitoring of the seizure-related changes in extracellular glutamate and γ-aminobutyric acid concentration in bilateral hippocampi following development of amygdaloid kindling, 20(3). ; 1995. p. 213-9.
120. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, et al. N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of γ-aminobutyric acidB receptor function. J Pharmacol Exp Ther 2003;307: 322-30.
121. Urwyler S, Gjoni T, Koljatic J, Dupuis DS. Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 2005;48: 343-53. (Pubitemid 40249997)
122. Vlachou S, Markou A. GABAB receptors in reward processes. Adv Pharmacol 2010;58: 315-71.
123. Waldmeier PC, Kaupmann K, Urwyler S. Roles of GABAB receptor subtypes in presynaptic auto- and heteroreceptor function regulating GABA and glutamate release. J Neural Transm 2008;115(10): 1401-11.
124. Xi ZX, Stein EA. Nucleus accumbens dopamine release modulation by mesolimbic GABA receptors an in vivo electrochemical study. Brain Res 1998;798: 156-65. (Pubitemid 28342031)
125. Xu J, Li C, Yin XH, Zhang GY. Additive neuroprotection of GABAA and GABAB receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology 2008;54(7): 1029-40.
126. Xu F, Peng G, Phan T, Dilip U, Chen, Chernov-Rogan T, et al. Discovery of a novel potent GABAB receptor agonist. Bioorg Med Chem Lett 2011;21(21): 6582-5.
127. Yamada J, SaitowF, Satake S, Kiyohara T, Konishi S. GABA(B) receptor-mediated presynaptic inhibition of glutamatergic and GABAergic transmission in the basolateral amygdale. Neuropharmacology 1999;38: 1743-53. (Pubitemid 29430249)
128. Yoder RM, Pang KC. Involvement of GABAergic and cholinergic medial septal neurons in hippocampal theta rhythm. Hippocampus 2005;15: 381-92. (Pubitemid 40668357)
129. ZhouW, Mailloux AW, Jung BJ, Edmunds Jr HS,McGinty JF. GABA(B) receptor stimulation decreases amphetamine-induced behavior and neuropeptide gene expression in the striatum. Brain Res 2004;1004: 18-28. (Pubitemid 38368059)